Benlysta (belimumab) is a prescription medication used to treat active systemic lupus erythematosus (SLE) and active lupus nephritis. It can be given as an intravenous (IV) infusion or an injection ...
MONDAY, June 30, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved an autoinjector of Benlysta (belimumab) for subcutaneous injection in patients ≥5 years of age with active ...
With this approval, pediatric patients aged five years and older with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration. PHILADELPHIA--(BUSINESS WIRE)-- ...
The approval makes belimumab (Benlysta) the first at-home treatment in its class for patients 5 years and older with systemic lupus erythematosus (SLE). The FDA approved GSK’s belimumab (Benlysta) ...
The FDA has expanded the approval of belimumab to include pediatric patients 5 to 17 years of age with active lupus nephritis. The Food and Drug Administration (FDA) has expanded the approval of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results